American Century Companies’s Mersana Therapeutics MRSN Stock Holding History

American Century Companies’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-451	Closed	-$113K	–	1306
2018 Q3	$113K	Sell	451 -1,288	-74%	-$432K	﹤0.01%	1248
2018 Q2	$776K	Buy	+1,739	New	+$763K	﹤0.01%	1135

Other funds holding MRSN

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

American Century Companies's MRSN Position: Q4 2018 in Review

American Century Companies sold out of Mersana Therapeutics (MRSN) in Q4 2018, closing a stake of 451 shares — an estimated $113K sold.

American Century Companies first reported a position in MRSN in Q2 2018 and held it in 2 quarters. The position peaked at $776K in Q2 2018. 48 funds tracked by Wall St. Rank hold MRSN as of Q4 2018.

American Century Companies reported no remaining Mersana Therapeutics position as of Q4 2018 after selling out during the quarter.
American Century Companies sold 451 Mersana Therapeutics shares in Q4 2018, an estimated $113K.
American Century Companies first reported a position in Mersana Therapeutics in Q2 2018 and held it in 2 quarters.
American Century Companies's Mersana Therapeutics position peaked at $776K in Q2 2018.
48 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2018.

Based on American Century Companies's 13F filing for Q4 2018, filed 13 Feb 2019.